Literature DB >> 31784031

EGF-A peptides: A promising strategy for PCSK9 inhibition.

Bertrand Cariou1, Wieneke Dijk2.   

Abstract

Entities:  

Keywords:  Hypercholesterolemia; LDLR; Lipid-lowering drugs; PCSK9; Small peptides

Mesh：

Substances：

Year:  2019        PMID： 31784031     DOI： 10.1016/j.atherosclerosis.2019.11.010

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  3 in total

1.  Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways.

Authors:  Yu Yuefeng; Lin Zhiqi; Chen Yi; Zhu Keyu; Wan Heng; Wang Yuying; Wang Ningjian; Yu Yuetian; Gu Xinjie; Zhang Yihao; Lu Yingli; Xia Fangzhen
Journal:  Int J Endocrinol       Date:  2022-05-13       Impact factor: 2.803

Review 2.  Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations.

Authors:  Alexander M Markin; Igor A Sobenin; Andrey V Grechko; Dongwei Zhang; Alexander N Orekhov
Journal:  Front Pharmacol       Date:  2020-05-14       Impact factor: 5.810

Review 3.  PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.

Authors:  Qianyun Guo; Xunxun Feng; Yujie Zhou
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.